Search company, investor...

Founded Year

2005

Stage

Unattributed VC - III | Alive

Total Raised

$53.66M

Last Raised

$34.05M | 7 yrs ago

About OxThera

OxThera is a biopharmaceutical company focused on developing treatments for rare kidney diseases, specifically targeting Primary Hyperoxaluria. The company's main product, Oxabact, is an orally administered biotherapy designed to reduce oxalate levels in patients by promoting its secretion from plasma into the gut and degrading it there, thereby protecting the kidneys from damage. OxThera primarily serves the healthcare sector, with a focus on providing novel treatment options for rare kidney diseases. It was founded in 2005 and is based in Stockholm, Sweden.

Headquarters Location

Regeringsgatan 111

Stockholm, 111 39,

Sweden

+46 8 660 02 23

Loading...

Loading...

OxThera Patents

OxThera has filed 16 patents.

The 3 most popular patent topics include:

  • oxalates
  • amines
  • cannabinoids
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/27/2018

4/27/2021

Ion channels, Kidney diseases, Rare diseases, Gastrointestinal tract disorders, Autosomal recessive disorders

Grant

Application Date

9/27/2018

Grant Date

4/27/2021

Title

Related Topics

Ion channels, Kidney diseases, Rare diseases, Gastrointestinal tract disorders, Autosomal recessive disorders

Status

Grant

Latest OxThera News

Global Short Bowel Syndrome Market is Anticipated to Reach US$ 3.66 Billion by 2031, Expanding at a Whopping 27% CAGR: TMR Report

Sep 7, 2023

Companies Covered  Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc. Key Findings of the Market Report In 2021, a sizable portion of the distribution channel segment's revenue is anticipated to come from online and retail pharmacies. The dominance is attributable to the rise in retail and online pharmacies in nations like the United States, the United Kingdom, India, and others. A large variety of GLP-2-based pipeline items for short bowel syndrome is the primary reason for the GLP-2 segment's dominance. Hospital pharmacies are anticipated to occupy a sizable portion of the market due to the industry's growing need for cutting-edge medications to treat ailments like Crohn's disease, one of the leading causes of short bowel syndrome. Market Trends for Short Bowel Syndrome Over the past several years, small bowel syndrome has become more common everywhere. The rise in patients receiving whole parenteral nourishment can be blamed for this. Short bowel syndrome is predicted to have a prevalence of four cases per million and an incidence of three cases per million. The precise incidence of the illness is unknown, and it is assumed based on the number of persons receiving parenteral feeding. The rise in frequency and incidence of uncommon diseases is probably what will drive the global market's expansion. There are now many additional treatments being tested in clinical trials for the management of short bowel syndrome, and there are no approved medications for the illness worldwide. The market's best insights begin with a simple request – get your sample now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346 Short Bowel Syndrome Market Regional Outlook Various reasons are propelling the growth of the short bowel syndrome market in different regions. These are: The expansion of the short bowel syndrome market in North America is being driven by the presence of a sizable patient pool embracing cutting-edge medications and needing new treatment alternatives. It is projected that the availability of a broad variety of pipeline items as well as the extended usage of authorized pharmaceuticals to treat adults as well as kids would support market growth in this area over the course of the projection period. Asia Pacific is predicted to have the most rapid CAGR throughout the projection period. The market expansion in this area is fueled by the direct participation of large companies, substantial investments in research and development for the creation of novel pharmaceuticals, and a growing emphasis on GLP-2-based medication clinical trials. Global Short Bowel Syndrome Market: Key Players Market players for short bowel syndrome are involved in regulatory approvals, the creation of new services, acquisitions, and joint ventures with other businesses. The short bowel syndrome market will probably grow internationally as a result of these tactics over the coming years. The following companies are well-known participants in the global short bowel syndrome market: Takeda Pharmaceutical Company Limited 2021 The FDA designated Apraglutide, a long-acting GLP-2 analog of the next generation being researched for uncommon gastrointestinal (GI) illnesses, as an orphan drug for the treatment of acute graft-versus-host disease (aGVHD). Receiving an allogeneic hematopoietic stem cell transplant can cause GVHD, a severe, uncommon illness in which the patient's healthy cells are attacked by the donor's immune cells. In the first quarter of 2022, VectivBio AG intends to start a phase 2 study testing Apraglutide for the treatment of aGVHD. Hanmi Pharm. Co. Ltd. 2021 Hanmi Pharm Co. Ltd. disclosed that the United States Food and Drug Administration has given LAPS GLP-2 Analog (HM15912), a treatment for short bowel syndrome, fast-track designation. With the use of the company's platform technology, called Labscovery, a novel biopharmaceutical called LAPS GLP-2 Analog is being created for short-bowel syndrome. The condition has a survival rate of under 50% and impairs children and teenagers' growth adversely. It affects around 24.5 out of every 100,000 infants. For Customization or Any Other Queries, Get in Touch with Our Industry Experts at - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=13346 Global Short Bowel Syndrome Market Segmentation Product About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports. Contact:

OxThera Frequently Asked Questions (FAQ)

  • When was OxThera founded?

    OxThera was founded in 2005.

  • Where is OxThera's headquarters?

    OxThera's headquarters is located at Regeringsgatan 111, Stockholm.

  • What is OxThera's latest funding round?

    OxThera's latest funding round is Unattributed VC - III.

  • How much did OxThera raise?

    OxThera raised a total of $53.66M.

  • Who are the investors of OxThera?

    Investors of OxThera include Kurma Partners, IDInvest Partners, Industrifonden, Brohuvudet, Sunstone Capital and 10 more.

  • Who are OxThera's competitors?

    Competitors of OxThera include Cerecin, MaxCyte, NGM Biopharmaceuticals, Pique Therapeutics, BIND Therapeutics and 7 more.

Loading...

Compare OxThera to Competitors

A
Arcion Therapeutics

Arcion Therapeutics is a company with a focus on providing lifestyle-oriented content across various domains. The company offers a range of articles and guides on topics such as compact bike pumps, instant photo printing, vaping, jewelry sets, electric bikes, touch screen technology, mechanical bulls, home decor, textiles, and stationery. These offerings aim to inform and assist consumers in making lifestyle choices and engaging in DIY activities. It is based in Baltimore, Maryland.

E
EnzymeRx

EnzymeRx is a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role.

A
AngioChem

AngioChem is a clinical-stage biotechnology company focused on developing pharmaceuticals for central nervous system diseases. The company specializes in creating Engineered Peptide Compounds (EPiC) that can cross the blood-brain barrier to treat a variety of brain diseases, including brain cancer, lysosomal storage disorders, and pain. AngioChem's products are designed to address medical needs that are currently unmet due to the challenges posed by the blood-brain barrier. It was founded in 2003 and is based in Montreal, Quebec.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Cerecin Logo
Cerecin

Cerecin is a healthcare company that focuses on brain health. The company develops a range of products including pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products, all aimed at addressing conditions ranging from memory impairment to severe neurological diseases. Cerecin was formerly known as Accera. It was founded in 2001 and is based in Singapore, Singapore.

S
SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.